Current Immunotherapy: Progress With Adoptive Cellular Therapies and Combinations

Source: Targeted Oncology, February 2020

The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.^1,2 Today, cancer immunotherapies, all of which recruit the body’s own immune system to target and eliminate cancer cells, represent a rapidly expanding and paradigm-shifting arsenal in cancer treatment. Immunotherapies that have gained regulatory approval and/or are in clinical development include immune checkpoint blockade agents, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, and adoptive or engineered T cell–based therapies (FIGURE 1).^3–5